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Developmental Transcriptional Enhancers: A Subtle
Interplay between Accessibility and Activity
Considering Quantitative Accessibility Changes between Diﬀerent Regulatory
States of an Enhancer Deconvolutes the Complex Relationship between
Accessibility and Activity
Marta Bozek and Nicolas Gompel*
Measurements of open chromatin in speciﬁc cell types are widely used to
infer the spatiotemporal activity of transcriptional enhancers. How reliable are
these predictions? In this review, it is argued that the relationship between the
accessibility and activity of an enhancer is insuﬃciently described by simply
considering open versus closed chromatin, or active versus inactive
enhancers. Instead, recent studies focusing on the quantitative nature of
accessibility signal reveal subtle diﬀerences between active enhancers and
their diﬀerent inactive counterparts: the closed silenced state and the
accessible primed and repressed states. While the open structure as such is
not a speciﬁc indicator of enhancer activity, active enhancers display a higher
degree of accessibility than the primed and repressed states. Molecular
mechanisms that may account for these quantitative diﬀerences are
discussed. A model that relates molecular events at an enhancer to changes
in its activity and accessibility in a developing tissue is also proposed.
1. Introduction
Open chromatin structure has long been associated with active
functional elements of the genome.[1,2] The destabilization
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or eviction of histones is a necessary step for
the exposure of recognition sites of eﬀector
DNA binding proteins such as transcription
factors (TFs), polymerases, and insulator
proteins.[3,4] This level of DNA exposure in a
chromatin context can be proﬁled genome-
wide with sensitive and quantitative assays
involving nuclease digestion (deoxyribonu-
clease I hypersensitive sites sequencing,
DNase-seq[5]), transposase fragmentation
(assay for transposase-accessible chromatin
using sequencing, ATAC-seq[6]), or cross-
linking and phenol–chloroform extraction
to separate protein-bound and protein-free
DNA fragments (formaldehyde-assisted iso-
lation of regulatory elements sequencing,
FAIRE-seq[7]). While accessible chromatin
conformation is not limited to distal cis-
regulatory elements,[4] it has been widely
used as a marker of transcriptional enhancers (reviewed in ref.
[8]). In combination with other chromatin and sequence fea-
tures, accessibility has been used not only to annotate genomic
positions of enhancers,[9] but also to predict their spatiotemporal
activity.[4,10] Several recent publications, however, highlight the
limitations of the predictive power of accessibility, suggesting
that the relationship between accessibility and activity is more
complex.
In this review, we focus on developmental enhancers and
discuss how regulatory events at the enhancers impact their ac-
cessibility. We ﬁrst review the current knowledge and limitations
of using accessibility as a signature of enhancer activity. We then
show how our picture of their relationship is reduced by com-
monly describing accessibility and activity only in binary terms:
open versus closed, active versus inactive. We go on to present re-
cent ﬁndings that emphasize quantitative changes in accessibility
between diﬀerent regulatory states of enhancers. We discuss the
known and plausible mechanisms that establish the accessibility
of enhancers and later quantitatively modulate it during en-
hancer operation. We conclude with a model of temporal control
of accessibility that links molecular events at the enhancers
with changes in their activity and accessibility in a developing
tissue.
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2. An Imperfect Correlation between Enhancer
Accessibility and Enhancer Activity
In a canonical example,[1] enhancers are accessible exclu-
sively in the cell type where they are active, that is where they
promote transcription of their target gene. During embryonic
development, the chromatin of cell-type speciﬁc enhancers
(e.g., regulating axis patterning genes, growth control genes,
cell diﬀerentiation genes) becomes selectively open, which
correlates well with the timing of their activity in vivo.[11,12]
The fact that accessibility of enhancers is a strong predictor of
their spatiotemporal activity has been also demonstrated with
computational models.[10,13]
Alongside reports conﬁrming the correlation between ac-
cessibility and activity of enhancers, an increasing number of
publications questions this simple one-to-one relationship.[8,14,15]
While active enhancers are indeed characterized by open chro-
matin, they can be also accessible in other cell types or at
other developmental timepoints, as demonstrated by the fol-
lowing studies. Arnold et al.[16] deployed a massively parallel
reporter assay STARR-seq (self-transcribing active regulatory
region sequencing) to identify cell-type speciﬁc enhancers in
two Drosophila melanogaster cell lines, derived from ovaries
and embryonic macrophages. The authors found a remarkable
mismatch with DNase-seq accessibility proﬁles, whereby about
a ﬁfth of the enhancers active in only one cell type were acces-
sible in both cell types. Similarly, Shashikant et al.[17] observed
that enhancers exclusively active in primary mesenchyme cells
(PMCs) of the sea urchin embryo were also characterized by
signiﬁcant accessibility in non-PMC lineages, and were already
open several hours before activation of their target genes.
Although McKay and Lieb[11] concluded a strong correlation
between accessibility and temporal activity of enhancers in the
course of D. melanogaster embryogenesis, close inspection of
their data reveals that some enhancers displayed FAIRE-seq
signal already 2–3 h prior to expression of the reporter gene.
These examples illustrate several potential reasons for the
observed discrepancies between the spatiotemporal activity and
accessibility of enhancers. First, as demonstrated by McKay and
Lieb,[11] the degree of the spatial and temporal overlap between
the measured accessibility and activity depends on the resolution
of experiments. While accessibility and activity might strongly
correlate between broadly deﬁned developmental stages, there
might be a discrepancy between the exact timing of their estab-
lishment. Second, limited purity of samples (e.g., isolated from
complex tissues or fast progressing developmental processes)
can lead to contamination of accessibility proﬁles,[18] in partic-
ular producing signiﬁcant signal over closed and presumably
inactive enhancers. Finally, comparisons between accessibility
measured at endogenous loci and activity measured with trans-
genic enhancer reporter assays should be done with caution.
Sequences tested outside of their endogenous genomic context
do not necessarily provide an accurate picture of their regulatory
potential. In fact, it has recently been highlighted that reporter
assays produce both false positives and false negatives, and that
their performance is cell-line dependent.[19,20] The results can be
confounded by the use of partial enhancer sequences that miss
certain transcription factor binding sites (TFBS),[21] but also by
diﬀerences in the chromatin context for integrated transgenes[22]
or by limited chromatinization of episomal vectors.[23,24] For ex-
ample, it has been reported that an enhancer may show activity
in the episomal STARR-seq assay even if in the same cell type
its endogenous counterpart does not promote transcription and
is marked by repressive histone marks.[16] Thus, STARR-seq
tests the overall potential of a genomic region to function as a
transcriptional enhancer (independent of the cell line), rather
than characterize its cell-type speciﬁc activity.
In summary, we still lack a consensus on how well the ac-
cessibility of enhancers predicts their spatiotemporal activity. To
some extent, the reported discrepancies may result from techni-
cal challenges of assessing enhancers’ accessibility and activity in
their endogenous context, including interpretation of enhancer
reporter assays. Here, we propose that these contrasting results
may also reﬂect biological phenomena, and could be reconciled
by considering diﬀerent degrees of accessibility (quantitative ac-
cessibility) and diﬀerent regulatory states of enhancers. As we
discuss in subsequent sections, this creates a more comprehen-
sive framework to study the causal relationship between accessi-
bility and activity.
3. Binary Distinction between Open and Closed
Chromatin Conceals Quantitative Accessibility
Diﬀerences
A vast majority of studies only consider a binary distinction be-
tween open and closed chromatin. In spite of a wide dynamic
range of ATAC-seq, DNase-seq, and FAIRE-seq, most analysis
is performed after peak calling, and is restricted to sets of open
regions with signiﬁcant signal enrichment. Thus, the measured
quantitative variation in accessibility is reduced to binary terms
(open versus closed intervals), raising certain caveats. First, the
exact deﬁnition of open regions, and more importantly their bi-
ological relevance, depends on arbitrary signiﬁcance thresholds,
and varies with the diﬀerent speciﬁcity and sensitivity of peak
calling algorithms.[25,26] Second, such a simpliﬁed view of chro-
matin organization can conceal relevant quantitative diﬀerences
between accessibility proﬁles of enhancers in diﬀerent cell types.
Even if in two diﬀerent samples an enhancer is identiﬁed as open
by a peak caller, it might still display signiﬁcantly diﬀerent levels
of accessibility.[15]
In that sense, there is little focus in the literature on the quan-
titative aspect of accessibility, other than in the context of de novo
enhancer discovery. In one approach, the accessibility proﬁle
of a small cell population is compared with the corresponding
whole-organism sample, which represents an average of all
cell types. Genomic intervals that display signiﬁcantly higher
accessibility, and thus interpreted as speciﬁcally open in the
given cell population, have been indeed shown to drive cell-type
speciﬁc transcription.[27,28] Other studies have identiﬁed novel
enhancers using quantitative accessibility diﬀerences between
well-separated cell types and timepoints. Shashikant et al.[17]
(discussed above) demonstrated that PMC-speciﬁc enhancers
displayed higher ATAC-seq signal in the cell type of their activity
as compared to non-PMC lineages. Uyehara et al.[29] identiﬁed
a set of genomic intervals that remained accessible during
an entire window of D. melanogaster wing development, yet
displayed a quantitative increase or decrease of their FAIRE-seq
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signal at diﬀerent timepoints. Notably, these temporally dynamic
regions drove transcription of a reporter gene at the timepoint
that coincided with their highest accessibility. Importantly,
both studies identiﬁed cell-type speciﬁc enhancers based on
the empirical observation that activity coincides with elevated
accessibility. While providing a simple rule for de novo discovery
of enhancers, they did not oﬀer an explanation for the residual
accessibility in the cell type where the regulatory elements did
not promote transcription.
To conclude, the binary distinction between open and closed
chromatin does not exploit the full quantitative potential of the
genome-wide accessibility assays. Yet, the quantitative informa-
tion might be meaningful to understand the reported discrep-
ancies between enhancer accessibility and activity. For instance,
when inactive enhancers are detected as open, how often do they
display lower accessibility signal than the active enhancers?
4. Inactive Enhancers Encompass Multiple
Regulatory States with Diﬀerent Chromatin
Organizations
The binary classiﬁcation that we underscored for enhancer acces-
sibility also applies to activity, a context in which enhancers are
usually classiﬁed as either active or inactive. This reﬂects the bi-
nary read-out of reporter assays and, more generally, stems from
our interpretation of enhancers as simple on and oﬀ switches.
However, enhancers exist in multiple regulatory states, and
transition between them during development and in response
to external stimuli (reviewed in refs. [30, 31]). While an active
enhancer can be unambiguously deﬁned as one that promotes
transcription from the target promoter, an inactive enhancer can
in fact correspond to several states, which diﬀer not only in terms
of their regulatory potential but also chromatin organization.
Active enhancers are bound by co-activators (e.g., p300 histone
acetyltransferase and theMediator complex) and are actively tran-
scribed by RNA polymerase II into enhancer RNA (eRNA).[32,33]
They are characterized by accessible, nucleosome-depleted chro-
matin organization,[1] and exhibit H3K4 methylation (H3K4me)
together with H3K27 acetylation (H3K27ac).[34,35] Inactive en-
hancers, however, can be classiﬁed into three diﬀerent regulatory
states: 1) silenced, 2) repressed, and 3) primed. For the sake
of this review, we deﬁne silenced enhancers as sequestered in
compact chromatin, depleted of active histone modiﬁcations
and devoid of TF binding. Importantly, we distinguish silenced
enhancers from repressed elements that are subject to direct
repression by sequence-speciﬁc TFs. As regulation by TFs re-
quires exposure of their binding sites, repressed enhancers are
expected to display some degree of accessibility.[15,36] Moreover,
repressed enhancers can be also simultaneously occupied by
activating TFs, as illustrated by enhancers involved in axis
patterning during D. melanogaster embryogenesis.[21,37] These
elements are targeted both by activators and repressors, and it is
the stoichiometry and aﬃnity of TF binding that determines the
net eﬀect on transcription of the target gene. While repressed en-
hancers share the H3K4me signature with active elements, they
are characterized by lower acetylation levels of histones, in par-
ticular by loss or reduction of H3K27ac.[38,39] The third inactive
state corresponds to enhancers primed for future activation (and
possibly repression),[40] including a class of poised enhancers in
mammalian embryonic stem cells.[35] While primed enhancers
are occupied by TFs and co-regulators, they do not receive
suﬃcient regulatory input to promote transcription from the
target promoters. Primed enhancers display similar chromatin
features as repressed elements.[41] They are characterized by
accessible chromatin conformation and exhibit H3K4me in the
absence or reduction of H3K27ac.[35,40,42] Poised enhancers ad-
ditionally exhibit repressive H3K27 trimethylation (H3K27me3)
that is associated with Polycomb Repressive Complex 2.[43]
Few studies provide information on how accessibility changes
in quantitative terms as enhancers transition between regula-
tory states, and we still lack a systematic comparison between
all states in diﬀerent multiple organisms. Some studies report
very similar levels of nucleosome depletion when active, primed,
and poised enhancers are compared in the same cell type.[35,40]
However, such comparisons might be misleading since they are
based on the mean signal across multiple elements. We know
from examination of individual enhancers in D. melanogaster
embryos[15] that the range of accessibility signal between indi-
vidual elements in the same regulatory state can diﬀer even by
one order of magnitude. It is more informative then to examine
accessibility changes as the same set of enhancers transitions be-
tween diﬀerent states. In such comparisons from mouse cells,
progression from the poised or primed state to the active state is
accompanied by increased accessibility.[42,44] Several studies inD.
melanogaster revealed that repressed enhancers are characterized
by reduced accessibility in comparison to their active state, while
still remaining open.[15,36,45] In fact, compaction into inaccessible
chromatin was shown to be a gradual process, which occurs with
a considerable delay upon repression of enhancers.[29] Thus, in-
activation of transcription by a repressor TF and loss of enhancer
accessibility are distinct regulatory events that take place on dif-
ferent time scales.
The notion of inactive enhancer conceals diﬀerences in the
regulatory potential and chromatin organization between 1) si-
lenced elements that are sequestered in compact chromatin, and
2) repressed or 3) primed elements that are both accessible and
subject to dynamic regulation. While accessibility of repressed
and primed enhancers does not correlate with the expression of
their target genes, it still oﬀers a cell-type and time-point speciﬁc
indication of TF binding and regulatory decisions. Importantly,
these two enhancer states can be distinguished from active
elements by their reduced signal when considering quantitative
accessibility. On these bases, we propose that the systematic
characterization of quantitative accessibility signatures for dif-
ferent enhancer states might improve our ability to predict them
genome-wide.
5. Resolving Enhancer Accessibility in Space
and Time
Besides considering the quantitative aspect of accessibility and
diﬀerent regulatory states of enhancers, our view on their mutual
relationship can be also improved by an increased spatiotem-
poral resolution of accessibility proﬁles in complex tissues.
This has been achieved thanks to the development of ATAC-
seq,[6] which allows for a considerable reduction of the starting
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material, even down to single cells.[46] Using ATAC-seq, a hand-
ful of recent publications focusing on the early embryogenesis
in D. melanogaster have explored in great detail how enhancer
accessibility varies both along the temporal and spatial axes of
development.[15,45,47,48] Additionally, by considering quantitative
accessibility diﬀerences, they provided valuable insights into
chromatin organization of diﬀerent enhancer states.
EarlyD. melanogaster embryogenesis oﬀers several advantages
for examining enhancer activity with high spatiotemporal resolu-
tion. In this well-studied paradigm for body patterning (reviewed
in refs. [49 50]), a set of enhancers regulates the establishment
of spatial coordinates immediately after zygotic genome activa-
tion. As these elements are targeted both by activators and repres-
sors whose distribution is spatially restricted along the body axes,
they exist in multiple regulatory states in the pre-gastrulation
embryo.[21,37,51] A large number of these enhancers have been val-
idated and characterized with diﬀerent experimental approaches,
including identiﬁcation of their input TFs and target genes.[52]
While the pre-gastrulation embryo consists of 6000 nuclei, each
with a unique transcriptional proﬁle,[53] it has a simple morphol-
ogy and can be easily subjected to genetic manipulation and me-
chanical dissection.
The temporal dynamics of enhancer accessibility have recently
been surveyed with two diﬀerent experimental approaches. First,
using ATAC-seq on tightly staged individual D. melanogaster em-
bryos, Blythe and Wieschaus[47] resolved enhancer accessibility
changes to 3min intervals. The authors demonstrated that acqui-
sition of accessibility by enhancers, and thus their priming, pre-
ceded that of their target promoters. Second, Cusanovich et al.[48]
performed single-cell ATAC-seq on broader embryonic collec-
tions and computationally ordered individual nuclei into tempo-
ral trajectories based on their accessibility proﬁles. As a result,
the authors recreated rapid transitions of cell identities during
the earliest embryogenesis and identiﬁed enhancers character-
ized by dynamic accessibility changes. Single-cell ATAC-seq also
revealed considerable spatial heterogeneity of accessibility pro-
ﬁles at a single developmental timepoint.
Spatial heterogeneity was conﬁrmed by two other studies that
performed a quantitative analysis of accessibility proﬁles of en-
hancers patterning the anteroposterior (AP) axis. Haines and
Eisen[45] applied ATAC-seq to cryosliced anterior and posterior
halves of the embryo, while in ref. [15] we performed genetic tag-
ging and aﬃnity-based isolation of nuclei from seven domains
along the AP axis. Both approaches demonstrated that the en-
hancers, while remaining open in the entire embryo, were char-
acterized by elevated accessibility in the embryonic domain in
which they promoted transcription of their target gene. On the
other hand, they displayed reduced accessibility in the domain in
which they did not drive transcription. In our study,[15] we also
provided a simple framework for analyzing genomic signal from
complex samples, demonstrating that the ATAC-seq signal ob-
tained from each embryonic domain was a weighted average of
accessibility signatures of active and inactive enhancer states. Im-
portantly, as activity of the enhancers was assessed through ex-
pression patterns of enhancer-reporter constructs, neither study
could discriminate between the two classes of inactive enhancers:
the primed and the repressed state.
In conclusion, proﬁling enhancer accessibility with high spa-
tial and temporal resolution allows for linking quantitative
changes in accessibility with diﬀerent enhancer states in a com-
plex developing tissue. The recent studies highlight the dynamic
evolution of enhancer accessibility in time, but also reveal that
at a single time point enhancer can display diﬀerent accessibility
proﬁles in diﬀerent cell populations.
6. Enhancer Accessibility is Controlled at Diﬀerent
Scales, from Broad Domains to Single Enhancers
The precise and dynamic pattern of accessibility of developmen-
tal enhancers points to a tight regulation of their chromatin state.
At least three non-exclusive modes of accessibility control have
been examined in the literature. They may represent diﬀerent
ranges of regulation, as suggested by others,[54] from 1) broad
chromosome domains controlled by the Polycomb/Trithorax sys-
tem to 2) the initiation of accessibility of individual enhancers by
pioneer transcription factors (PFTs; this section), and to 3) the lo-
cal ﬁne-tuning of accessibility during the operation of enhancers
(see next section). However, the molecular mechanisms that gov-
ern each of these modes are not resolved to the same depth. Little
is known about how they are coordinated.
6.1. Accessibility of Broad Chromatin Domains and Individual
Enhancers is Regulated by Diﬀerent Mechanisms
The ﬁrst control of chromatin accessibility is extrinsic to en-
hancer sequences and is mediated by the Polycomb-group
proteins (PcG) and Trithorax-group proteins (TrxG) from a
particular class of cis-regulatory elements called PREs and TREs,
respectively. PREs and TREs govern chromatin compaction over
broad chromosomal domains, in the order of tens or hundreds of
kilobases, by recruiting chromatin modiﬁers and remodelers.[55]
In the plethora of studies on PcG and TrxG, the chromatin state is
evaluated through diﬀerent histone modiﬁcations[56–60] and the
actual chromatin accessibility is not directly examined. It is there-
fore diﬃcult to reconcile the pattern of local, discrete, and dy-
namic peaks of accessibility seen at individual enhancers[15,29,36]
with the broad control of chromatin states from PREs and TREs.
Do subtle interactions between PREs and individual enhancers
modulate local accessibility within a broad Polycomb repressive
domain? Exploring this question during D. melanogaster em-
bryogenesis, Koenecke et al.[41] made an interesting observation:
the enrichment of the Polycomb repressive mark H3K27me3 at
individual enhancers is strongly correlated with their distance to
the nearby PRE, rather than with the local repression by a TF. To
further understand the role of this broad control at individual en-
hancers, it would be necessary to directly probe their accessibility
with DNase-seq or ATAC-seq upon mutation of a nearby PRE
or TRE.
The second control of enhancer accessibility is built-in in the
form of binding sites for PTFs. PTFs are deﬁned as proteins that
initiate accessibility, and thus prime enhancers,[61,62] by interact-
ing directly with nucleosomal DNA.[63] Their occupancy at en-
hancers induces local nucleosome depletion that is required for
the subsequent binding of the patterning activator and repres-
sor TFs.[14,18,64–68] Recent studies from D. melanogaster show that
the establishment of accessibility is directly mediated through
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PTF binding sites within the enhancer,[14] and that the degree
of openness positively correlates with their number.[65,69] In a
classical view, while PTFs prime enhancers, they are insuﬃcient
to activate transcription of the target gene, a job left to activator
TFs.[14,70,71] However, recent studies indicate that the distinction
between PTFs as permissive factors and patterning TFs as in-
structive factors is somewhat blurred. For example, the activator
TFs p53[72] and Bicoid,[73] while operating in completely diﬀer-
ent physiological contexts, appear to promote both accessibility
and activity of some of their respective target enhancers. Further-
more, a classical PTF, Zelda, has been recently demonstrated not
only to be required for the maintenance of enhancer accessibility
during the operation of patterning TFs,[71] but also to bear itself
a transcription activating domain.[74]
6.2. Enhancers Preserve their Local Accessibility Proﬁles Outside
of their Endogenous Loci
Although genomic context inﬂuences their activity, enhancers
are deemed to function as independent modules.[75] How is this
reﬂected at the level of their accessibility? We have seen above
that accessibility of enhancers is determined by intrinsic infor-
mation and quantitatively linked to the number of PTF binding
sites,[65,69,70] suggesting a certain degree of autonomy. How then
does the broader genomic context (e.g., nearby PREs and TREs)
inﬂuence the local accessibility of an enhancer?[76] To test what
aspect of enhancer accessibility is inherently determined by its
sequence, in particular in ectopic reporter constructs, we reana-
lyzed ATAC-seq proﬁles from our recent study.[15] We compared
accessibility signal of selected enhancers active inD.melanogaster
embryos under two genetic conditions (Figure 1): 1) embryos
containing only an endogenous enhancer (blue line) and 2) trans-
genic embryos with an additional copy of the same enhancer in
a genomic integration site (green line). Remarkably, the trans-
genic enhancers displayed very similar chromatin organization
as their endogenous counterparts. Boundaries between the ac-
cessible portion of the enhancer and the inaccessible ﬂanking
regions were maintained at a nearly base-pair resolution. Fur-
thermore, localmodulation of accessibility, including positioning
of nucleosomes, was also highly conserved in the transgenic en-
hancers. We concluded that the 0.7–1.7 kb of the DNA sequences
that we placed in the genomic integration site were autonomous
to determine and ﬁne-tune their own accessibility with almost a
base-pair resolution. It is important to note that the transgenic
enhancers were placed in a permissive environment of a tested
integration site.[77] As transgenes show variable activity depend-
ing on their genomic position,[78] it would be interesting to test
how the boundaries and the overall degree of enhancer accessi-
bility change in diﬀerent genomic integrations.
6.3. Interplay of Internal and External Mechanisms of
Accessibility Regulation Coordinates Activity Across Multiple
Enhancers
External elements such as PREs/TREs and the internal bind-
ing sites for PTFs may represent two diﬀerent, yet complemen-
tary, regulatory mechanisms. PREs have been demonstrated to
modulate higher-order chromatin structure, including looping,
enhancer-promoter pairing, formation of topologically associat-
ing domains (TADs), and interactions between TADs.[58,79] These
3D chromatin rearrangements may aﬀect the TF target search
(the ability of a TF to ﬁnd its target enhancer in the nucleus),[80]
or the frequency of interactions between an enhancer and its
distant target core promoter. By contrast, built-in TFBS for
PTFs determine local chromatin decompaction of individual
enhancers.[14,65] As they expose TFBS to activator and repressor
TFs, they play a permissive role in enhancer function. By deter-
mining boundaries of enhancer accessibility, PTFs might in fact
deﬁne the exact composition of TFBS contributing to enhancer
regulation.[13] Interestingly, in the context of D. melanogaster em-
bryogenesis, the same factor that primes the direct decompaction
of hundreds of enhancers, Zelda, also appears to seed higher-
order structures of the genome.[81] This is perhaps where the co-
ordination of diﬀerent levels of chromatin accessibility happens.
Along the same lines, another PTF, FOXA1, was showed to facili-
tate deposition ofH3K4me by recruiting a chromatinmodiﬁer.[82]
In conclusion, we can distinguish two scales at which accessi-
bility of an enhancer is regulated. Locally, PTFs determine acces-
sibility and boundaries of individual elements. On a larger scale,
Polycomb and Trithorax systems determine the global permis-
siveness of a chromatin domain to regulatory activity, potentially
coordinating the action of multiple enhancers.
7. Enhancer Activity May Directly Modulate
Enhancer Accessibility
While PTFs seed and maintain enhancer accessibility,[14,71] ad-
ditional local mechanisms may subsequently modulate it dur-
ing enhancer operation, resulting in the observed quantitative
diﬀerences in accessibility levels between the primed and active
states,[42,44] as well as the active and repressed states.[15,45] Accessi-
bility signal of the ATAC-seq andDNase-seq assays represents the
frequency with which naked DNA is targeted by the transposase
or nuclease in the chromatin context. Therefore, the distribution
and intensity of the signal are inﬂuenced both by nucleosome
location along the sequence and aﬃnity of histones to DNA.[83]
We consider here three plausible mechanisms that, by aﬀecting
nucleosome positioning and stability, quantitatively modulate ac-
cessibility of diﬀerent enhancer states.
First, progression of the RNA polymerase during transcrip-
tion of active enhancers[84] results in nucleosome displacement,
and transiently increases DNA exposure.[85] Thus, the elevation
in accessibility that is observed upon transition of enhancers
from their primed to the active state might be a direct con-
sequence of their transcription into eRNA. Indeed, it has
been shown that signal-induced changes in transcription of
genes correlate well with fold changes in eRNA levels at their
corresponding enhancers.[86] Additionally, eRNA transcription
has been proposed to play an active role in chromatin remodel-
ing, maintaining the accessibility of enhancers to transcriptional
regulators.[87] However, recent studies contest this model by
demonstrating that eRNA transcription occurs also at inactive
enhancers with repressive histone marks[88] or by identifying
active enhancers with undetectable eRNA transcription.[89]
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Interestingly, the rate of transcription initiation at the target
promoter has been shown to correlate more strongly with the
overall enhancer accessibility than the amount of transcribed
eRNA.[88]
Second, non-pioneer patterning TFs are capable of acting in
a collaborative fashion to evict nucleosomes, by competing with
histones for binding to their TFBS.[90,91] If active enhancers are
targeted by a larger number of regulators than their primed coun-
terparts, we can envision that this higher TF load would result in
lower nucleosome stability. Although TFs can locally protect their
binding sites from cleavage by a transposase or a nuclease,[6,92]
this eﬀect is unlikely to counterbalance the overall impact of nu-
cleosome destabilization on enhancer accessibility.[15] Patterning
TFs bind to DNA only transiently compared to histones, their
residence time being in the order of seconds,[93,94] thus confer-
ring greater accessibility of their TFBS. Although TFs might con-
tribute to the overallmaintenance of enhancer accessibility under
a law of mass action as we have just described, it is important to
note that activator and repressor TFs have been also reported to
have opposing eﬀects on the nucleosome stability. During early
D. melanogaster embryogenesis, for instance, the activator Bicoid
promotes accessibility of its target enhancers,[73] while the repres-
sor Knirps increases their local nucleosome occupancy.[39] The
stabilization of nucleosomes by repressors could explain the ob-
served reduction in enhancer accessibility in the transition from
an active to a repressed state. Furthermore, if a nucleosome that
is stabilized by a repressor TF overlaps an activator TFBS, this
might create a simple mechanism for integrating activating and
repressive regulatory inputs at the enhancer.[95] The idea that dif-
ferent TFs may impact local enhancer accessibility in diﬀerent
ways is additionally supported by studies that have examined
the correlation between predicted TF motifs in regulatory ele-
ments and their overall accessibility[4] or cell-to-cell variation in
accessibility.[46] Yet, this notion has never been thoroughly tested
with experiments. Furthermore, it is still to be determined how
the collaborative destabilization of nucleosomes by TFs interplays
with their stabilization by repressors, and how this impacts en-
hancer accessibility.
Finally, TFs may also actively shape accessibility through lo-
cal modulation of epigenetic marks, by recruiting histone acetyl-
transferases and deacetylases via their co-activators and co-
repressors, respectively.[96] Indeed, enhancers in an active state
display higher levels of H3K27ac than in a primed or repressed
state.[41] While this per se does not indicate a causal link, Li and
Arnosti[39] showed that overexpression of the repressor Knirps in
D. melanogaster embryos led to the decrease of H4 acetylation at
its target enhancers.[97] As lysine acetylation reduces nucleosome
stability and increases accessibility of linker DNA,[98–100] diﬀer-
ential action by co-activators and co-repressors at the enhancer
could result in the observed quantitative diﬀerences between the
active, primed, and repressed states.[15]
Overall, in addition to the broad and local mechanisms seed-
ing enhancer accessibility that were discussed in the previous
section, accessibility of enhancers can be also ﬁne-tuned during
their operation, as a consequence of multiple regulatory events.
Enhancer transcription as well as nucleosome stabilization and
destabilization by non-pioneer patterning TFs could account for
the quantitative accessibility diﬀerences that we observe between
diﬀerent enhancer states.
8. A Temporal Model of the Quantitative
Relationship between Enhancer Accessibility and
Activity
The considerations above lead us to propose a model (Figure 2)
to represent the onset of enhancer activity, for instance in the
context of embryonic development. We consider a hypothetical
enhancer driving gene expression in a particular spatial domain
of an embryo (presumptive domain highlighted with green cell
outlines in Figure 2E–H) and as of a certain stage of develop-
ment. Several molecular events take place around this enhancer
Figure 1. Enhancer accessibility information is contained in the enhancer sequence. A) In this experimental setup,[15] an endogenous enhancer (ho-
mozygous) drives transcription of its target gene in the D. melanogaster embryo, while its transgenic copy integrated at the attP2 site[103] (homozygous)
drives transcription of a nuclear tag. When mapping ATAC-seq reads to the reference genome, we did not include a sequence of the reporter construct.
As a result, reads originating from the transgenic enhancer and those originating from the endogenous enhancer mapped to the same position (en-
dogenous locus). For each enhancer, we compare accessibility signal in the endogenous locus between the strain that carries an additional transgenic
copy of the element (referred to as a transgenic strain; green line, mean over two replicates) and the three remaining strains that serve as a reference
and only contain the endogenous enhancer (referred to as a reference strain; blue line, mean from three stains with two replicates each). As expected,
signal intensity over the enhancer is on average twice higher in the transgenic strain than in the reference (IN ratio, grey shading). Likewise, accessibil-
ity of regions ﬂanking each enhancer is highly comparable between the two strains (OUT ratio). Importantly, the four enhancer sequences considered
here, which have been identiﬁed through genetic dissections or predicted clustering of TFBS,[104] are not accessible along their entire sequence in the
endogenous locus. All enhancer sequences contain a distinct peak of ATAC-seq signal that neighbors an inaccessible region (blue lines). Notably, the
distribution of the accessibility signal originating from the transgenic strains (green lines) is very similar to the signal of reference strains with the en-
dogenous enhancer alone (blue lines). The two strains show a strong and signiﬁcant correlation between their ATAC-seq signal at individual base pairs,
both within the enhancer as well as at the upstream and downstream ﬂanking regions (r = Pearson’s correlation coeﬃcient indicated in each domain; for
all coeﬃcients: p-value < 0.001). We would not expect to observe such a conservation of the distribution of ATAC-seq signal at the base-pair resolution,
or a clear diﬀerence between the accessible and inaccessible portion of the element, if local accessibility of the transgenic enhancer in the integration
site diﬀered from its accessibility proﬁle in the endogenous locus. Tracks represent the distribution of Tn5 transposase cuts, after normalization (as in
Bozek et al.[15]) and smoothing with a moving average of 10 bp. Position of enhancers in their endogenous loci is marked with grey shading, and they are
ﬂanked by 500 bp upstream and downstream for reference: B)Dichaete D_(+4), C) giant gt_(-3), D) hunchback hb_anterior, and E) Kruppel Kr_CD1. Upper
right of each panel: ratio of the total number of transposase cuts between the transgenic and the reference strains, within the enhancer’s sequence (IN)
and in the two 500 bp blanking regions (OUT). Samples represent whole-embryo controls from Bozek et al.[15] which, apart from the diﬀerent transgenic
enhancer, are genetically identical: D1 control, D4 control, D5 control, and D7 control. The ATAC-seq proﬁles were obtained at the same developmental
timepoint. Genomic coordinates according to Release 5.57 of the D. melanogaster reference genome.[105] Coordinates and names of the enhancers as
in Segal et al.[104] Exact sequences and details on the transgenic strains and ATAC-seq analysis in Bozek et al.[15]
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Figure 2. Transitions between enhancer states in a developing tissue. The ﬁgure depicts A–D) transitions between four enhancer states in developing
tissue, and E–H) the corresponding changes in their activity status (red, yellow, and green nuclei) and in their measured accessibility signal (insets in
E–H; green: accessibility signal in the presumptive gene expression domain, white: accessibility signal outside the domain). At the earliest time point (A),
an inactive silenced enhancer (blue halo in A–D) is encapsulated in compact chromatin, resulting in no regulatory activity and inaccessible sequence in
most cells (red nuclei in E), even in the prospective domain where this enhancer will later be turned on (green cell outlines in E–H). The speciﬁc binding
of a pioneer transcription factor (PTF) (blue oval in A–D, expressed in gray cells in E–H) will result in local nucleosome depletion of the enhancer
sequence (B) and signiﬁcant increase in its accessibility (yellow nuclei in F–G). This new primed state exposes binding sites for transcription factors
that mediate the transactivation (brown and green shapes in B–D). The binding of TFs is not suﬃcient to activate the enhancer (C), but it may suﬃce to
initiate interactions with the target core promoter and the basal transcription machinery, priming the enhancer for a quick transcription onset. Finally,
the expression of a key activator (magenta hexagon) and its binding to the enhancer sequence conditions the enhancer transition from primed to active
state (D), initiates transcript production (green nuclei in H), and leads to further increase of the enhancer’s accessibility (green inset in H).
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and its target promoter before transcripts start to accumulate,
from a silenced inaccessible state (red nuclei in Figure 2E) to
a primed and accessible state (yellow nuclei in Figure 2F,G),
and to an active state (green nuclei in Figure 2H). In its original
silenced state, the enhancer sequence shows a high nucleosome
occupancy (Figure 2A), both in the presumptive expression
domain of its target gene (Figure 2E: green cell outlines) and
in the cells that will never express this gene (Figure 2E: gray
and white cells). This inaccessibility of DNA prevents binding
of patterning TFs that govern the spatial activity. The mean
enhancer accessibility (e.g., ATAC-seq signal) both inside and
outside of the presumptive expression domain of the gene is
very low, at the same level as the surrounding genomic positions
(green and white insets in Figure 2E). In certain nuclei, however,
the enhancer may become transiently accessible as histones
may stochastically dissociate from its sequence. When a PTF
(Figure 2A: blue oval), expressed homogeneously or broadly in
a cell population (Figure 2E-H: gray cells), binds the nucleoso-
mal DNA, the enhancer transitions to a primed state: a ﬁrst,
permissive step toward activity. The PTF initiates the regulated
depletion or displacement of nucleosomes (Figure 2F,G: yellow
nuclei). Because this process is likely not synchronous among
nuclei, the establishment of accessibility across the tissue may
take some time.[47] This will ﬁrst manifest itself as a small peak
of ATAC-seq signal (green and white insets in Figure 2F,G) at the
enhancer locus. The peak will grow in height (but not in width)
over time as the action of the PTF unfolds among nuclei and
the proportion of primed states increases in the embryonic do-
main. Concurrently, the enhancer sequence that is now exposed
becomes “open for business,” which has two consequences for
the primed enhancer. The patterning TFs can bind their cog-
nate TFBS on the enhancer (Figure 2B), and the enhancer can
initiate a search of its target promoter, to ﬁnally loop onto it[101]
(Figure 2C). While the mere looping is not suﬃcient to activate
transcription (Figure 2G: yellow nuclei), it has been shown for
some developmental genes to prime the target promoter by
stabilizing a paused RNA polymerase.[101,102] A key signal is
missing for the transcription to start, for instance an activator
that is not expressed yet at this stage. Once this key signal comes
in (Figure 2D: magenta hexagon), the enhancer switches to the
active state and the transcripts start to accumulate (Figure 2D,H).
Interactions of activator TFs with nucleosomes and chromatin
remodelers as well as eRNA transcription may further promote
nucleosome destabilization at the enhancer, resulting in a higher
ATAC-seq peak in the enhancer activity domain (green inset
in Figure 2H). Nevertheless, because of the transient nature
of TF binding and some stochasticity in enhancer–promoter
interactions, enhancers in some cells may transiently revert to
a primed state (few yellow nuclei in cells with green outlines in
Figure 2H), even in the presence of the full set of activators.
9. Conclusions and Prospects
Our understanding of the relationship between accessibility and
activity of enhancers has recently been advanced through im-
proved spatiotemporal resolution and a greater focus on the
quantitative aspect of accessibility. Subtle diﬀerences in the de-
gree of accessibility between primed, repressed, and active en-
hancers reconcile contradictory reports in the literature and paint
a ﬁner picture of accessibility modulation at enhancers.
The transition between diﬀerent regulatory states explainswhy
enhancers display accessibility in a broader developmental time
window than their activity. The fact that at a single time point en-
hancers are open also outside of their activity domain indicates
that in a complex tissue primed and repressed states can exist
alongside the active enhancers. Therefore, the accessibility of en-
hancers is not a speciﬁc signature of their spatiotemporal activ-
ity, understood as promoting transcription of the target gene. Yet,
accessibility is still a strong indicator of the regulatory activity at
the enhancer itself. The accessible repressed and primed states,
since targeted by pioneer and patterning TFs, are a site of tight
regulatory control by the cell.
Nevertheless, while accessibility per se does not imply activity,
active enhancers are characterized by a higher degree of acces-
sibility than the other states. This observation comes with two
important consequences. Systematic characterization of quanti-
tative accessibility signatures of diﬀerent enhancer statesmay aid
their genome-wide identiﬁcation. Second, it opens questions on
the fundamental mechanisms that ﬁne-tune chromatin organi-
zation at enhancers.
Finally, as a perspective in this context, we identify two ques-
tions that represents a frontier for the ﬁeld. First, through which
mechanisms is the initial accessibility promoted by PTFs main-
tained and modulated during activation or repression of en-
hancers? Second, what is the relative contribution of the over-
all TF occupancy, TF valence (activators versus repressors) and
enhancer transcription (eRNA) to the enhancer’s quantitative ac-
cessibility, and how is their action coordinated?
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